Clinical pharmacist in oncology palliative medicine: drug compliance and patient adherence

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F23%3A10478883" target="_blank" >RIV/00179906:_____/23:10478883 - isvavai.cz</a>

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=sRn_PdOJr0" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=sRn_PdOJr0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/spcare-2023-004212" target="_blank" >10.1136/spcare-2023-004212</a>

Result language

angličtina

Original language name

Clinical pharmacist in oncology palliative medicine: drug compliance and patient adherence

Original language description

Objectives Most patients in palliative oncology care are polymorbid and thus treated with multiple drugs. The therapeutic effect and safety of these drugs can be compromised by drug/drug interactions, but also by wider problems such as polypharmacy and compliance. The clinical pharmacist is, therefore, responsible for risk analysis and prevention. Our prospective open label non-randomised clinical study evaluated the importance of a clinical pharmacist in the palliative care team. Methods A total of 250 outpatients were included in the clinical study: 126 women (50.4%) and 124 men (49.6%), with a mean age of 71 years (range 21-94 years; SD 11.9). The patients had the performance status scale 0-3 ((x) over bar = 2). Clinical examinations were performed on a monthly basis (n=509 check-up visits). The clinical pharmacist prepared an educational chart for all medications used after each visit and evaluated any drug-related problems. Follow-up was 6 months. Results This study found a significant association between drug related-problems and polypharmacy (p&lt;0.001). A low risk of drug-rfelated problems was observed during the initial visit, that is, 68 female (27.2%) and 25 male (10.4%) patients. A greater clinical-pharmaceutical risk was observed among the patients taking antihypertensive drugs (p=0.003) and/or beta blockers (p=0.048). Conclusion This study confirms the essential role of a clinical pharmacist in oncology palliative care. The feedback obtained from the patients showed a notable improvement in their quality of life. Further, this clinical study confirmed the need for a personalised approach in palliative oncology care.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NU20-09-00045" target="_blank" >NU20-09-00045: Quality of life analysis in palliative care of cancer patients – A personalized approach in specialized outpatients.</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

BMJ Supportive and Palliative Care

ISSN

2045-435X

e-ISSN

2045-4368

Volume of the periodical

13

Issue of the periodical within the volume

E3

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

"e1308"-"e1317"

UT code for WoS article

001009720000001

EID of the result in the Scopus database

2-s2.0-85164389922